Correction: Metformin Improves the Impairment of Cognitive Function Caused by Total Abdominal Irradiation via the miR-34a-5p/BDNF/CREB Axis.
Confidence:
0.15
· 7 полей извлечено
Идентификация (6 полей)
Механизм действия (21 полей)
Mechanism
—
0.00
Mutations (obesity/lean)
—
0.00
Activity (obesity)
—
0.00
Activity temporal
—
0.00
Energy balance
—
0.00
Appetite
—
0.00
Fat metabolism
—
0.00
Lipolysis
—
0.00
Thermogenesis
—
0.00
Muscle metabolism
—
0.00
Inflammation
—
0.00
Glucose metabolism
—
0.00
AA metabolism
—
0.00
Hormonal pathways
—
0.00
Cell death
—
0.00
Adipocyte fibrosis
—
0.00
Upstream (biochem)
—
0.00
Upstream (physiol)
—
0.00
Downstream (biochem)
—
0.00
Downstream (physiol)
—
0.00
PTMs
—
0.00
Экспрессия (8 полей)
Tissue expression
—
0.00
In vitro
—
0.00
In vivo
Metformin improves cognitive impairment caused by total abdominal irradiation via miR-34a-5p/BDNF/CREB axis; Hesperetin-enhanced metformin alleviates cognitive impairment via gut-brain axis in type 2 diabetes rats; Empagliflozin enhances neuroplasticity in rotenone-induced parkinsonism; APOE4-dependent association between metformin use and Alzheimer's disease-related cortical thickness in older adults with type 2 diabetes
0.90
In silico
—
0.00
Genetic association
APOE4-dependent association between metformin use and Alzheimer's disease-related cortical thickness
0.90
Ex vivo
—
0.00
Animal model
Total abdominal irradiation model; Type 2 diabetes rats; Rotenone-induced parkinsonism model
0.90
Diet/model
Type 2 diabetes model; Rotenone-induced parkinsonism model; Total abdominal irradiation model
0.90
Клиника (11 полей)
Drug
Metformin
0.90
Indication
Cognitive impairment
0.80
Patient subgroups
—
0.00
Safety concerns
—
0.00
Off-target
—
0.00
Trial stage
—
0.00
Pharma competitors
—
0.00
AE severity
—
0.00
MOA weight loss
—
0.00
Endpoints
—
0.00
Approved
True
0.90